UltraMD
Skin tone. Skin texture. A clearer focus.
Fractional non-ablative thulium laser for tone, texture and superficial skin quality.
Your medical assessment determines suitability.
- 011927 nm thulium wavelength
- 02Fractional non-ablative delivery
- 03IntelliTrak™ roller tracking
Areas of application
Photodamage & pigment · Texture & pores · Low-downtime revitalisation
An informed choice.
What the evidence can tell you — and where its limits matter.
Sources checkedEvidence & expectations
A randomized split-face study in 20 people compared a 1927 nm thulium laser with a fractional picosecond laser. Both improved measured photoageing features, but recovery differed. This supports discussion of the wavelength class, not proof that every UltraMD setting or combination produces the same effect.[1]
Preparation & recovery
Allow for visible skin changes during recovery: the trial recorded redness, peeling and crusting over the first two weeks. Actual recovery depends on the settings and your skin, rather than a universal “lunchtime” promise.[1]
Risks & limitations
Pigment can darken or lighten after an inflammatory procedure. Melasma can recur and needs an ongoing management plan; a laser is not a universal cure for brown patches. Establish the diagnosis before selecting the device.[2]
Compare your options
For uneven tone, first distinguish sun damage, melasma and other pigment disorders. Skin care and medical management may be more relevant than escalating laser intensity.[2]
Different approaches to discuss
These links explain different targets. They are not personalised recommendations.
UltraMD skin renewalK-LUXEPicoSure Pro FocusSources & further reading
- Controlled clinical trialFractionated picosecond versus 1927 nm thulium laser: randomized trialWu et al. · Lasers in Surgery and Medicine · 2021
- Professional guidanceMelasma: diagnosis and treatmentAmerican Academy of Dermatology
- Manufacturer informationUltraMD: platform informationCynosure LutronicManufacturer information explains the platform or named protocol; it is not independent evidence of clinical benefit.
How we use evidence
A controlled trial compares interventions in defined groups; an uncontrolled cohort cannot, alone, establish causality. A review depends on the quality of its included studies. We distinguish these sources from manufacturer information and identify when findings do not directly apply to the platform or protocol.
The date records when sources were checked for this guide. It is not a statement of individual clinical review, product authorisation or confirmation of the clinic’s available configuration.
This guide supports a conversation with your clinician. It does not determine your suitability or replace individual aftercare instructions.
Where this technology fits.
Explore the treatment pathways that use this platform, including the sequence and what to discuss at your assessment.